about
Fungal contamination of bedding.EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance.Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectCryptic species and azole resistance in the Aspergillus niger complex.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsAnidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.Posaconazole: the case for therapeutic drug monitoring.Multi-resistant aspergillosis due to cryptic species.Mechanisms of Antifungal Drug Resistance.Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoterAdverse reactions to voriconazole.Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Rate of cyp51A mutation in Aspergillus fumigatus among lung transplant recipients with targeted prophylaxis.Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients.An invertebrate model to evaluate virulence in Aspergillus fumigatus: the role of azole resistance.Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis.Sub-cutaneous phaeohyphomycosis caused by Cladophialophora devriesii in a United Kingdom resident.Understanding the implementation of 'sick day guidance' to prevent acute kidney injury across a primary care setting in England: a qualitative evaluation.Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.Getting messier with TIDieR: embracing context and complexity in intervention reporting.Major variations inAspergillus fumigatusarising within aspergillomas in chronic pulmonary aspergillosisIn vitro susceptibility of non-Aspergillus allergenic fungal species to azolesFlucytosine therapeutic monitoring: 15 years experience from the UKMulti-azole resistance in Aspergillus fumigatusPhaeohyphomycosis caused by Exophiala salmonis
P50
Q34477762-E8416E2E-3EE2-4757-8E39-167E21A4FE8BQ34596993-A9083EE4-A7A7-4152-A54D-F15FC903F75DQ35066763-0B9B254F-2A27-4528-843F-7ED0F1DCFFF2Q35127913-24F8E19C-D966-4CE7-880A-DB320938AC05Q35270458-7071F109-4859-491E-8B04-30C32911A39FQ35270758-ACF4657A-A981-4EE4-8CF2-12F51B48E037Q35689202-66C198D1-5000-41B6-90E4-326AEC65FC3AQ36171643-C4F28779-6EDE-4237-90C9-AE873DBEB8F7Q36505301-4E56EC61-3FE7-4D36-8921-03F99928AFFBQ36936353-955713A1-0E23-438F-90F5-936B3B4E1F82Q37263445-37594245-E8FA-4CFB-AAE2-7571E64E8A09Q37335725-C12A9ADC-8731-49D9-A82F-703D97B5EDF4Q37519843-D1F598D7-B529-4767-9204-322EF7FE3C91Q37783285-5714643A-A65B-4F21-824C-0D5D4C6D1A63Q37973020-92B88C7C-8E6B-4172-B1BF-FF15898A62E1Q38223608-3943F26B-9DA9-4F11-885A-17588C12610CQ38266675-673DFFC0-C0CA-4D5B-911A-7186E087FD85Q38726518-1B1AC110-C68B-41AE-8F6A-2055B3DCF558Q38918614-BEDD9B1B-45A6-4654-98AD-9CB71A986DDFQ39364669-CDD6DC63-AE27-4ABE-B210-D3CDEE67E0CFQ41554323-21404EF8-58C9-4661-B062-8A8B245A42EAQ41822618-4DD1EACC-6DA6-4ADD-A804-931E052E9D00Q42004623-84E26F63-E8CD-4461-9A13-DA17B62C055EQ42104497-678E850E-DB9F-4A79-9B8D-BB4A048CF4FBQ42930104-C8B66816-4ABB-4917-ABC2-CA18AD5AFDE6Q43293126-D0C14021-E106-49C4-98CF-DA88D08D586EQ44604285-765E3153-9BF1-40D4-B9CD-34F56749CC44Q45715063-81278831-C39D-416F-9FAD-2ABD9ECDBFCAQ47568169-7E8909F1-4EAD-4E30-8CDE-595256CC9905Q48217200-81465E02-7B69-411E-9FDA-DDE3EAB2456FQ56837233-D3E30205-28D7-48AE-8710-659AA3D60EF1Q56837266-15E28737-1AAF-4D88-8C92-75AB94EFFA09Q56837289-5C9D5CE6-C3AC-44FE-A5D5-46061B32A641Q56837308-4F7DA4C4-89D1-4DCD-8F63-B54E89D9131EQ79224068-074DC7DF-8A85-47C1-87D3-070F557B04AF
P50
description
researcher ORCID ID=0000-0003-0340-2016
@en
name
Howard S
@en
Howard S
@nl
type
label
Howard S
@en
Howard S
@nl
prefLabel
Howard S
@en
Howard S
@nl
P106
P31
P496
0000-0003-0340-2016